Robotic Automation of Cell Isolation to Streamline Cell Therapy Manufacturing

Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to scaling the manufacturing of these therapies. By standardizing critical workflows and operating seamlessly with GMP-compliant instruments, robots enable levels of throughput, reproducibility, and efficiency that were previously out of reach. 

In this talk, Dr. Fred Parietti, co-founder and CEO of Multiply Labs, will share how robotic biomanufacturing clusters are redefining what’s possible inside the cleanroom. As a case study, he will highlight the integration of the GenScript CytoSinct™ 1000 into the Multiply Labs robotic platform. This fully automated cell isolation workflow demonstrates how robotics can deliver higher consistency, streamline operations, and shorten production timelines - all while operating with validated, industry-leading tools. 

Attendees will learn how robotics improves the unit economics of cell therapy manufacturing, enables parallelism for higher throughput, and accelerates the automation process. More than incremental efficiency, this approach points to a new standard for scalable, automated cell therapy production.

Learning Objectives:

1. How robotics radically improves the unit economics of cell therapy manufacturing, increasing throughput, and accelerating timelines?

2. How the robotic system overcomes potential regulatory and process barriers by operating market-leading GMP instruments that are already deployed?

3. How can cell isolation be robotic automated utilizing GenScript CytoSinct and Multiply lab platform?